Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site.

W. Fairbrother,H. Christinger,Andrea G. Cochran,G. Fuh,Christopher J. Keenan,Clifford Quan,Stephanie K. Shriver,Jeffrey Y. K. Tom,James A. Wells,B. Cunningham

DOI: https://doi.org/10.1021/BI981931E

IF: 3.321

1998-12-04

Biochemistry

Abstract:Peptides that inhibit binding of vascular endothelial growth factor (VEGF) to its receptors, KDR and Flt-1, have been produced using phage display. Libraries of short disulfide-constrained peptides yielded three distinct classes of peptides that bind to the receptor-binding domain of VEGF with micromolar affinities. The highest affinity peptide was also shown to antagonize VEGF-induced proliferation of primary human umbilical vascular endothelial cells. The peptides bind to a region of VEGF known to contain the contact surface for Flt-1 and the functional determinants for KDR binding. This suggests that the receptor-binding region of VEGF is a binding "hot spot" that is readily targeted by selected peptides and supports earlier assertions that phage-derived peptides frequently target protein-protein interaction sites. Such peptides may lead to the development of pharmacologically useful VEGF antagonists.